Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Bullboard Posts
Post by stockarchangelon Dec 08, 2016 12:35pm
149 Views
Post# 25572231

Thoughts

ThoughtsWell, we got our update. And it basically sucks. On the subject of 1067, I find it incredulous that anyone could have viewed the negotiations as imminent at any point. What the h_ell was that video about last January? Was it misinterpretation, misconception, misunderstandind or some other "mis?" I've been here for well over 4 years (with others, may I add) and developed at least a couple dozen contacts. All of those contacts and their sources have seemingly been wrong over the last 12 months lol. Wishful thinking does not equal fact, constitute reality nor influence future events.
There are several topics in this update that probably deserved their own news releases and are almost certainly material or close to it. Instead of forcing shareholders to guess, regular updates would have helped immensely in maintaining inforrnational integrity, and perhaps influencing other investors. It's quite obvious 1067 was never as close as perceived and became a singular obsession for everyone. It doesn't cut it to now say, "......by the way, we also have all this other stuff happening."
There are also several statements that require further explanation. As a corporate document, this update is not very good, by any standard of measurement. It is incomplete and confusing. I'm not happy.
Bah, humbug.


Bullboard Posts